Art. -Nr.: HY-N0462

Corilagin

(Synonyms: NP-004255)

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

Corilagin, a gallotannin, has anti-tumor, anti-inflammatory and hepatoprotective activities. Corilagin inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin also inhibits the growth of Staphylococcus aureus with a MIC of 25 μg/mL. Corilagin shows anti-tumor activity on hepatocellular carcinoma and ovarian cancer model. Corilagin shows low toxicity to normal cells and tissues.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.96%
CAS. Nr.: 23094-69-1
Formel: C₂₇H₂₂O₁₈
Molecular Weight:634.45

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Corilagin Chemical Structure

CAS. Nr.: 23094-69-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen :

In Vitro

Corilagin (0-50 μM, 24 h) inhibits SGC7901 and BGC823 cell growth, and the cells became rounded^[2].
Corilagin (0-30 μM, 24 h) induces SGC7901 and BGC823 cell apoptosis^[2].
Corilagin (0-30 μM, 24 h) decreased the protein levels of procaspase-8, -9 and -3 and increases cleaved PARP in SGC7901 and BGC823 cell^[2].
Corilagin (0-30 μM, 24 h) induces autophagy in SGC7901 and BGC823 cell (enhancement of acidic vesicles, increased the level of LC3II)^[2].
Corilagin (0-30 μM, 24 h) induces ROS generation in SGC7901 and BGC823 cell^[2].
Corilagin (40 μM, 24 or 48 h) induces G2 cell cycle arrest and apoptosis in Hey and SKOv3ip cells^[3].
Corilagin (0-80 μM, 1-3 days) inhibits the secretion of TGF-β1 in Hey, SKOv3ip and HO8910PM cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

SGC7901 and BGC823 cell
Concentration:

0, 10, 20, 30, 40 and 50 µM
Incubation Time:

24 h
Result:

Inhibited cell proliferation in a concentration-dependent manner.

Western Blot Analysis^[2]

Cell Line:

SGC7901 and BGC823 cell
Concentration:

0, 10, 20, 30 µM
Incubation Time:

24 h
Result:

Decreased the protein levels of procaspase-8, -9 and -3 and increased the level of cleaved PARP.

In Vivo

Corilagin (15 mg/kg, i.p., for 7 days) shows anti-tumor activity in Hep3B hepatocellular carcinoma^[4].
Corilagin (0-20 mg/kg, i.p.) prevents APAP-induced hepatotoxicity in mice^[5].
Corilagin (10 and 100 mg/kg, i.p.) ameliorates Bleomycin-induced pulmonary fibrosis in mice^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Hep3B hepatocellular carcinoma mouse model^[4].
Dosage:

15 mg/kg
Administration:

Intraperitoneal injection (i.p.)
Result:

Inhibited tumor growth without toxic effects.

Animal Model:

APAP-induced hepatotoxicity in mice^[5]
Dosage:

0, 1, 5, 10, 20 mg/kg
Administration:

Intraperitoneal injection (i.p.)
Result:

Decreased APAP-induced serum ALT level, hepatic myeloperoxidase (MPO) activity, cytokines (TNF-α, IL-1β, and IL-6) production, malondialdehyde (MDA) activity, and ERK/JNK MAPK and NF-κB protein expressions.

Chemical Information

CAS. Nr. 23094-69-1
Appearance Solid
Molecular Weight 634.45
Formel C₂₇H₂₂O₁₈
Color White to off-white
SMILES

O[C@@H]1[C@@H](COC(C2=C(C3=C(O)C(O)=C(O)C=C34)C(O)=C(O)C(O)=C2)=O)O[C@@H](OC(C5=CC(O)=C(O)C(O)=C5)=O)[C@H](O)[C@H]1OC4=O
Synonyms

NP-004255
Structure Classification
- Phenols
- Polyphenols
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (8)

All In Vivo Efficacy StudyHistological Imaging/StainingFlow CytometryELISA

Sort by:

Journal Impact Factor

Front Immunol

Corilagin Ameliorates Con A-Induced Hepatic Injury by Restricting M1 Macrophage Polarization. [Abstract]

2022 Jan 13;12:807509. PMID: 35095894

Corilagin purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Jan 13;12:807509. [Abstract]

Mice were administered corilagin (25 mg/kg) intraperitoneally twice at time intervals of 12 h. After 1 h, mice were challenged with Con A (20 mg/kg body weight). Liver tissues were collected 12 h later. Corilagin treatment significantly reduced the MDA level and increased the activity of SOD compared with the Con A group.

Corilagin purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Jan 13;12:807509. [Abstract]

Mice were administered corilagin (25 mg/kg) intraperitoneally twice at time intervals of 12 h. After 1 h, mice were challenged with Con A (20 mg/kg body weight). Liver tissues were collected 12 h later. MPO levels in the corilagin-treated group were significantly reduced compared with those in the Con A-treated group.

Corilagin purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Jan 13;12:807509. [Abstract]

Mice were administered corilagin (25 mg/kg) intraperitoneally twice at time intervals of 12 h. After 1 h, mice were challenged with Con A (20 mg/kg body weight). Liver tissues were collected 12 h later. The results showed that corilagin treatment markedly attenuated hepatocyte apoptosis induced by Con A.

Corilagin purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Jan 13;12:807509. [Abstract]

Mice were administered corilagin (25 mg/kg) intraperitoneally twice at time intervals of 12 h. After 1 h, mice were challenged with Con A (20 mg/kg body weight). Liver tissues were collected 12 h later. Detection of the macrophage ratio in mouse hepatic mononuclear cells (HMNCs) by flow cytometry.

Corilagin purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Jan 13;12:807509. [Abstract]

Mice were administered corilagin (25 mg/kg) intraperitoneally twice at time intervals of 12 h. After 1 h, mice were challenged with Con A (20 mg/kg body weight). Liver tissues were collected 12 h later. Inflammatory cytokines interleukin (IL)-6, IL-12, and tumor necrosis factor-α (TNF-α) in the serum measured by ELISA.
Eur J Pharmacol

Corilagin alleviates cardiac ischemia-reperfusion injury by inhibiting ferroptosis via PI3K/AKT pathway. [Abstract]

2025 Nov 5:1006:178158. PMID: 40962010
World J Diabetes

Corilagin alleviates podocyte injury in diabetic nephropathy by regulating autophagy via the SIRT1-AMPK pathway. [Abstract]

2024 Sep 15;15(9):1916-1931. PMID: 39280180
Cancer Sci

CLG promotes mTOR/ULK1 pathway-mediated autophagy to inhibit OS development by inhibiting TRAF6-mediated FLT3 ubiquitination. [Abstract]

2024 Oct;115(10):3466-3480. PMID: 39118482
FASEB J

Corilagin enhances wound healing by modulating the macrophage phenotype in diabetic mice. [Abstract]

2025 Mar 15;39(5):e70439. PMID: 40052815
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Fitoterapia

Polyphenol-enriched extracts of Sarcopoterium spinosum fruits for counteracting lipid accumulation and oxidative stress in an in vitro model of hepatic steatosis. [Abstract]

2024 Jan:172:105743. PMID: 37952761
Ann Hematol

Corilagin induces pyroptosis in AML cells by activating the TXNIP-caspase-3-GSDME pathway. [Abstract]

2026 Feb 11;105(3):107. PMID: 41670696

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (157.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5762 mL

7.8808 mL

15.7617 mL

5 mM

0.3152 mL

1.5762 mL

3.1523 mL

10 mM

0.1576 mL

0.7881 mL

1.5762 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 2.5 mg/mL (3.94 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 5.88 mg/mL (9.27 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Li X, et al. Corilagin, a promising medicinal herbal agent. Biomed Pharmacother. 2018 Mar;99:43-50. [Content Brief]

[2]. Xu J, et al. Corilagin induces apoptosis, autophagy and ROS generation in gastric cancer cells in vitro. Int J Mol Med. 2019 Feb;43(2):967-979. [Content Brief]

[3]. Jia L, et al. A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways. BMC Complement Altern Med. 2013 Feb 15;13:33. [Content Brief]

[4]. Hau DK, et al. In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma. Phytomedicine. 2010 Dec 15;18(1):11-5. [Content Brief]

[5]. Liu FC, et al. Corilagin reduces acetaminophen-induced hepatotoxicity through MAPK and NF-κB signaling pathway in a mouse model. Am J Transl Res. 2020 Sep 15;12(9):5597-5607. [Content Brief]

[6]. Wang Z, et al. Corilagin attenuates aerosol bleomycin-induced experimental lung injury. Int J Mol Sci. 2014 May 30;15(6):9762-79. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.5762 mL	7.8808 mL	15.7617 mL	39.4042 mL
	5 mM	0.3152 mL	1.5762 mL	3.1523 mL	7.8808 mL
	10 mM	0.1576 mL	0.7881 mL	1.5762 mL	3.9404 mL
	15 mM	0.1051 mL	0.5254 mL	1.0508 mL	2.6269 mL
	20 mM	0.0788 mL	0.3940 mL	0.7881 mL	1.9702 mL
	25 mM	0.0630 mL	0.3152 mL	0.6305 mL	1.5762 mL
	30 mM	0.0525 mL	0.2627 mL	0.5254 mL	1.3135 mL
	40 mM	0.0394 mL	0.1970 mL	0.3940 mL	0.9851 mL
	50 mM	0.0315 mL	0.1576 mL	0.3152 mL	0.7881 mL
	60 mM	0.0263 mL	0.1313 mL	0.2627 mL	0.6567 mL
	80 mM	0.0197 mL	0.0985 mL	0.1970 mL	0.4926 mL
	100 mM	0.0158 mL	0.0788 mL	0.1576 mL	0.3940 mL

Keywords

Corilagin

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Corilagin

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Small Molecule Immuno-Oncology Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Antibacterial Compound Library

Medicine Food Homology Compound Library

Phenols Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Pattern Recognition Receptors Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Corilagin

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Corilagin Related Classifications

HY-N0462 Related Classifications